The investigational drug selpercatinib may benefit patients with lung cancer whose tumors have alterations in the RET gene, including fusions with other genes, according to results from a small clinical trial.
from Cancer Currents: An NCI Cancer Research Blog https://ift.tt/2ndM2jy
from Cancer Currents: An NCI Cancer Research Blog https://ift.tt/2ndM2jy